| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/02/2004 | EP1372739A2 Stabilized therapeutic and imaging agents |
| 01/02/2004 | EP1372736A2 Anti-neovasculature preparations for cancer |
| 01/02/2004 | EP1372724A2 Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| 01/02/2004 | EP1372723A1 Semi-allogenic anti-tumour vaccine with hla haplo-identical antigen-presenting cells |
| 01/02/2004 | EP1372722A1 Method for prophylaxis and treatment of porcine reproductive and respiratory syndrome |
| 01/02/2004 | EP1372720A1 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| 01/02/2004 | EP1372719A2 Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer |
| 01/02/2004 | EP1372718A2 Production and use of novel peptide-based agents for use with bi-specific antibodies |
| 01/02/2004 | EP1372717A2 Combination treatment of pancreatic cancer |
| 01/02/2004 | EP1372716A2 Blood cell production via activation of the hemoglobin scavenger receptor (cd163) |
| 01/02/2004 | EP1372715A2 Method for treating cancer using a33 specific antibodies and chemotherapeutic agents |
| 01/02/2004 | EP1372714A2 Method for inducing an immune response to polysaccharide bacterial antigens and to protein structures of virus capsids |
| 01/02/2004 | EP1372712A2 Equine herpesvirus vaccine |
| 01/02/2004 | EP1372710A2 Mva expressing modified hiv envelope, gag, and pol genes |
| 01/02/2004 | EP1372709A2 Intimins for the prevention or treatment of infections: i |
| 01/02/2004 | EP1372708A2 Vaccine for transcutaneous immunization |
| 01/02/2004 | EP1372706A2 A novel proteosome-liposaccharide vaccine adjuvant |
| 01/02/2004 | EP1372705A2 Leishmania vaccines |
| 01/02/2004 | EP1372704A1 Monocyte-specific particulate delivery vehicle |
| 01/02/2004 | EP1372698A2 Use of cytokines of the tgf-beta superfamily for the treatment and diagnosis of skin related disorders |
| 01/02/2004 | EP1372691A2 Mucin peptide with immunoenhancing properties |
| 01/02/2004 | EP1372690A2 93870, a human g-protein coupled receptor and uses therefor |
| 01/02/2004 | EP1372689A2 Use of ikk-beta inhibitors and method for discovery of said inhibitors |
| 01/02/2004 | EP1372682A2 Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
| 01/02/2004 | EP1372621A1 Novel use of tyrosine kinase inhibitor |
| 01/02/2004 | EP1372618A1 Colloidal suspension of nanoparticles based on an amphiphilic copolymer |
| 01/02/2004 | EP1372528A2 Mucosal boosting following parenteral priming |
| 01/02/2004 | EP1250146B1 Use of botulinum toxins for treating diabetes |
| 01/02/2004 | EP0831921B1 Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
| 01/02/2004 | EP0705109B2 Adjuvants for vaccines against respiratory syncytial virus |
| 01/02/2004 | EP0663008B1 Improvements in or relating to immune response modification |
| 01/02/2004 | EP0145783B2 Canine coronavirus vaccine |
| 01/01/2004 | US20040003418 Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer |
| 01/01/2004 | US20040002585 Mucin fusion polypeptide vaccines, compositions and methods of use thereof |
| 01/01/2004 | US20040002582 Miniprotein ligands and other polypeptides and methods for making and using same |
| 01/01/2004 | US20040002581 Peptides and use thereof in therapeutic agents against HIV infection |
| 01/01/2004 | US20040002537 Multiple sclerosis; central nervous system disorders; side effect reduction |
| 01/01/2004 | US20040002472 Vaccination or immunization using a prime-boost regimen |
| 01/01/2004 | US20040002470 Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease |
| 01/01/2004 | US20040002469 Administering genetic engineered polynucleotide which codes heat shock protein; induce immunology response |
| 01/01/2004 | US20040002460 Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's disease, and treatments and animal models produced therefrom |
| 01/01/2004 | US20040002440 Modulation gene expression; binding antigen to polypeptide; therapy for infection |
| 01/01/2004 | US20040002134 Novel nucleic acid sequences encoding human KIAA0768 protein-like and human protein PRO228-like polypeptides |
| 01/01/2004 | US20040002111 Atherosclerosis vaccine |
| 01/01/2004 | US20040002103 Synthetic ligation reassembly in directed evolution |
| 01/01/2004 | US20040002088 Identification and isolation of novel DNA and to the recombinant production of polypeptides having sequence similarity to Glial Cell line-derived Neurotrophic Factor Receptor (GDNFR) |
| 01/01/2004 | US20040002068 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 01/01/2004 | US20040002066 36 human secreted proteins |
| 01/01/2004 | US20040002061 Methods of using the signal to transmit and maintain influenza viral and foreign nucleic acid in virus and cells |
| 01/01/2004 | US20040002059 Screening method and a screening system capable of selecting agents capable of interfering with this protein-protein interaction; selection of agents capable of modulating this protein-protein interaction for treatment and control of PV |
| 01/01/2004 | US20040001867 Vectors for molecule delivery to CD11b expressing cells |
| 01/01/2004 | US20040001866 Genetic engineered polypeptides; bactericide |
| 01/01/2004 | US20040001864 Using antigens; genetic enginering; gene expression of capsid; heat resistance |
| 01/01/2004 | US20040001854 Isolated, genetic engineered polypeptide |
| 01/01/2004 | US20040001853 Genetic engineering; immunoglobulins; hepatitis virus ; induce immunology response |
| 01/01/2004 | US20040001852 Deactivation antigen protein; anticancer agents; Aids therapy |
| 01/01/2004 | US20040001851 Polyvalent immunogen |
| 01/01/2004 | US20040001850 Dna sequences; genetic engineering |
| 01/01/2004 | US20040001849 Antigen library immunization |
| 01/01/2004 | US20040001848 Alzheimer's disease; vaccines; induction immunology response |
| 01/01/2004 | US20040001847 Method and composition to elicit an effective autologous antitumoral immune response in a patient |
| 01/01/2004 | US20040001845 Polypeptide vaccine; Aids therapy; stimulant immunology response |
| 01/01/2004 | US20040001844 Lewis Y epitope-containing mucin fusion polypeptide vaccines, compositions and methods of use thereof |
| 01/01/2004 | US20040001843 Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections |
| 01/01/2004 | US20040001842 Inducing antibodies in situ; binding; antitumor agents, anticancer agents |
| 01/01/2004 | US20040001841 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 01/01/2004 | US20040001840 Cancer-linked gene as target for chemotherapy |
| 01/01/2004 | US20040001838 Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| 01/01/2004 | US20040001836 Mixture of polypeptide with carrier |
| 01/01/2004 | US20040001835 Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| 01/01/2004 | US20040001831 Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders |
| 01/01/2004 | US20040001829 Methods for selectively stimulating proliferation of T cells |
| 01/01/2004 | US20040001828 Treatment methods using anti-CD22 antibodies |
| 01/01/2004 | US20040001805 Prevention infections; gene therapy; insertion of genome; genetic engineered vaccine |
| 01/01/2004 | US20040001804 LLT uses thereof in immune system modulation |
| 12/31/2003 | WO2004001655A1 Methods of treating and preventing colitis involving il-13 and nk-t cells |
| 12/31/2003 | WO2004001425A2 Mhc class ii haplotype specific immunodominancy of peptides derived from rsv fusion (f) and attachement (g) proteins |
| 12/31/2003 | WO2004001424A1 Materials and methods for inductions of immune tolerance |
| 12/31/2003 | WO2004001381A2 Novel raag10 cell surface target and a family of antibodies recognizing that target |
| 12/31/2003 | WO2004001072A2 Method for diagnosis of colorectal tumors |
| 12/31/2003 | WO2004001035A1 Method for generating monoclonal antibodies |
| 12/31/2003 | WO2004001022A1 Probiotic propionibacterium jensenii 702 |
| 12/31/2003 | WO2004001014A2 Osteopontin, oligodendrocytes and myelination |
| 12/31/2003 | WO2004001007A2 Buffered formulations for concentrating antibodies and methods of use thereof |
| 12/31/2003 | WO2004001004A2 Membrane associated tumor endothelium markers |
| 12/31/2003 | WO2004000881A1 Dna sequence and recombinant production of the grass pollen allergen phl p4 |
| 12/31/2003 | WO2004000878A1 Immunogenic polypeptide isolated from Mycobacterium avium subspecies paratuberculosis and uses thereof |
| 12/31/2003 | WO2004000876A1 INFECTIOUS cDNA OF AN APPROVED VACCINE STRAIN OF MEASLES VIRUS, USE FOR IMMUNOGENIC COMPOSITIONS |
| 12/31/2003 | WO2004000873A2 Adjuvant-free peptide vaccine |
| 12/31/2003 | WO2004000872A2 Improved alphavirus vectors having attenuated virion structural proteins |
| 12/31/2003 | WO2004000343A1 Recombinant polypeptide for immunocastration and vaccine comprising the same |
| 12/31/2003 | WO2004000238A2 Utilization of mhc class ii binding motifs in immunization to produce immune serum, monoclonal antibodies and vaccines |
| 12/31/2003 | WO2004000209A2 Administration of therapeutic viruses |
| 12/31/2003 | WO2003088997A3 Reduction of unwanted immune reactions |
| 12/31/2003 | WO2003084568A3 Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations |
| 12/31/2003 | WO2003073918A3 Prevention of recurrence and metastasis of cancer |
| 12/31/2003 | WO2003072036A3 Treatment methods using anti-cd22 antibodies |
| 12/31/2003 | WO2003068811A3 Cytotoxic t-cell epitopes from chlamydia |
| 12/31/2003 | WO2003066095A3 MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING |
| 12/31/2003 | WO2003064607A3 Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |